CMES2 The Truth of the Matter: An Evidence-Based Review of the Newer Antihyperglycemic Agents for T2DM: A hot° seat™ Program

Program: CMES Ancillary Events
Clinical Session
Saturday, April 2, 2016: 6:30 PM-9:00 PM
Pacific Ballroom (The Renaissance)
Supported by an educational grant from AstraZeneca

Registration is required for this session:

Learning Objectives:

Upon completing this activity, learners will be better able to:

  • Review recent data on using agents within newer treatment classes (ie, DPP-4 inhibitors, GLP-1 RAs, and SGLT2 inhibitors), in complementary combinations with other antihyperglycemic agents and with insulin
  • Summarize current evidence pertaining to the effects of newer agents on cardiovascular events and cardiovascular mortality
  • Identify relevant patient characteristics influencing the selection of newer antihyperglycemic agents
7:00 PM

Vivian A Fonseca, MD, Medicine - Endo, Tulane University Health Science, New Orleans, LA
Nothing to Disclose: VAF
7:05 PM

Zachary T Bloomgarden, MD, Mount Sinai School of Medicine, New York, NY
Disclosure Not Provided: ZTB
7:20 PM

Derek LeRoith, MD, PhD, Division of Endocrinology, Diabetes and Bone Diseases, Icahn School of Medicine at Mount Sinai, New York, NY
Disclosure Not Provided: DL
7:35 PM

James R Gavin III, PHD, MD, Dept of Internal Med, Emory Univ Schl of Med, Fayetteville, GA
Disclosure Not Provided: JRG III
7:50 PM

Derek LeRoith, MD, PhD, Division of Endocrinology, Diabetes and Bone Diseases, Icahn School of Medicine at Mount Sinai, New York, NY
Disclosure Not Provided: DL
8:05 PM

Zachary T Bloomgarden, MD, Mount Sinai School of Medicine, New York, NY
Disclosure Not Provided: ZTB
8:20 PM

James R Gavin III, PHD, MD, Dept of Internal Med, Emory Univ Schl of Med, Fayetteville, GA
Disclosure Not Provided: JRG III
See more of: CMES Ancillary Events